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Cleḿent Despres,†,◆ Jing Di,‡,◆ Franco̧is-Xavier Cantrelle,† Zizheng Li,‡ Isabelle Huvent,†
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ABSTRACT: Self-assembly of the microtubule-associated
protein tau into neurotoxic oligomers, ﬁbrils, and paired
helical ﬁlaments, and cell-to-cell spreading of these patho-
logical tau species are critical processes underlying the
pathogenesis of Alzheimer’s disease and other tauopathies.
Modulating the self-assembly process and inhibiting formation
and spreading of such toxic species are promising strategies
for therapy development. A challenge in investigating tau self-
assembly in vitro is that, unlike most amyloidogenic proteins,
tau does not aggregate in the absence of posttranslational
modiﬁcations (PTM), aggregation inducers, or preformed seeds. The most common induction method is addition of
polyanions, such as heparin; yet, this artiﬁcial system may not represent adequately tau self-assembly in vivo, which is driven by
aberrant phosphorylation and other PTMs, potentially leading to in vitro data that do not reﬂect the behavior of tau and its
interaction with modulators in vivo. To tackle these challenges, methods for in vitro phosphorylation of tau to produce
aggregation-competent forms recently have been introduced (Despres et al. (2017) Proc. Natl. Acad. Sci. U.S.A., 114,
9080−9085). However, the oligomerization, seeding, and interaction with assembly modulators of the diﬀerent forms of tau
have not been studied to date. To address these knowledge gaps, we compared here side-by-side the self-assembly and seeding
activity of heparin-induced tau with two forms of in vitro phosphorylated tau and tested how the molecular tweezer CLR01, a
negatively charged compound, aﬀected these processes. Tau was phosphorylated by incubation either with activated
extracellular signal-regulated kinase 2 or with a whole rat brain extract. Seeding activity was measured using a ﬂuorescence-
resonance energy transfer-based biosensor-cell method. We also used solution-state NMR to investigate the binding sites of
CLR01 on tau and how they were impacted by phosphorylation. Our systematic structure−activity relationship study
demonstrates that heparin-induced tau behaves diﬀerently from in vitro phosphorylated tau. The aggregation rates of the
diﬀerent forms are distinct as is the intracellular localization of the induced aggregates, which resemble brain-derived tau strains
suggesting that heparin-induced tau and in vitro phosphorylated tau have diﬀerent conformations, properties, and activities.
CLR01 inhibits aggregation and seeding of both heparin-induced and in vitro phosphorylated tau dose-dependently, although
heparin induction interferes with the interaction between CLR01 and tau.
As one of the major molecular actors in Alzheimer’s disease(AD) and other tauopathies, including frontotemporal
dementia, progressive supranuclear palsy, corticobasal syn-
drome, Pick’s disease, and chronic traumatic encephalopathy,
the microtubule-associated protein tau has been investigated in
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the last few decades as an attractive, yet challenging,
therapeutic target.1−3 In humans, tau exists as six alternatively
spliced isoforms, which normally are bound to microtubules
and are thought to stabilize the microtubule structure. In
tauopathies, tau detaches from the microtubules and self-
assembles into neurotoxic oligomers and ﬁbrillar aggregates,
which are found in the brain as neuroﬁbrillary tangles (NFTs)
and other types of deposits.4
NFTs, one of the two characteristic proteinaceous lesions of
AD,4 faithfully correlate with clinical progression of the disease,
in contrast to the other lesion, amyloid plaques, which are
poorly associated with cognitive decline.5−7 Tau pathology
propagates through the brain in a reproducible temporal and
regional manner.8,9 In fact, immunostaining using monoclonal
antibody (mAb) AT8, which binds speciﬁcally to hyper-
phosphorylated tau, is used for AD staging.10 Nonetheless, as
in other proteinopathies, metastable tau oligomers have been
suggested to be a major neurotoxic agent and possibly the
main culprit responsible for impairing and eventually killing
susceptible neurons.11
The main components of NFTs in AD are tau paired helical
ﬁlaments (PHF) consisting of two helically twisted ribbons of
10−20 nm width with an 80 nm periodicity. In these insoluble
structures, tau transforms from a soluble, natively disordered
conformation into cross-β structures, typical of amyloid, which
encompass primarily its microtubule-binding domain (MTBD,
residues 244−372).12−15 A recent study using cryoelectron
microscopy on PHFs and straight ﬁlaments (SF) isolated from
patients with AD has deﬁned the structure of tau ﬁbrils and
highlighted a distinct structural arrangement in PHF and SF.16
In AD brain ﬁbrils, tau protoﬁlaments adopt a cross-β/β-helix
structure encompassing microtubule-binding repeats R3 and
R4. The core of the ﬁbrils is ﬂanked by a “fuzzy coat”
comprising the unfolded N- and C-terminal domains.17,18
In AD, all six isoforms of tau are found abnormally
hyperphosphorylated in PHFs.19−22 The majority of the
abnormal phosphorylation sites are distributed over ∼40
positions clustered in the proline-rich region (PRR) and C-
terminal domains ﬂanking the MTBD.22−24 Hyperphosphor-
ylation of tau in these regions is thought to cause its pathologic
aggregation,25−27 though the precise mechanism of this process
remains elusive. Interestingly, certain phosphorylation sites,
e.g., S262 in the MTBD and S214 in the PRR, have been found
to inhibit aggregation.28−30
Many studies have characterized the self-assembly process of
tau in vitro. However, because of the practical diﬃculty of
obtaining puriﬁed hyperphosphorylated or otherwise post-
translationally modiﬁed tau, in vitro aggregation of tau typically
is studied using tau forms devoid of posttranslational
modiﬁcations (PTMs), which do not aggregate spontaneously.
Fragments of tau containing the MTBD or parts thereof are
aggregation-prone, and their ﬁbrils may serve as a template to
promote the aggregation of full-length tau;15,31−35 yet, this
strategy does not alleviate the concern about the lack of
pathologically relevant PTMs. More commonly, in vitro
aggregation assays use external inducers, including polyanions,
such as heparin,36,37 RNA,38 and fatty acids, such as
arachidonic acid,39,40 or small anionic molecules41 that
stimulate the aggregation process through mechanisms that
are not fully understood.42−45 Although external aggregation
inducers may lead to formation of tau ﬁbrils that can be
morphologically similar to PHFs,18,36 the aggregation process
and structural details of these ﬁbrils may be distinct from those
of disease-relevant tau aggregates.16,46 Along these lines,
recently, tau ﬁbrils formed in vitro by addition of heparin or
RNA were found to contain substantial amounts of the
inducers and to disaggregate upon treatment with heparinase
or RNase, respectively.47 These ﬁndings are of particular
concern in view of recent data demonstrating that conforma-
tionally distinct tau “strains” display substantially diﬀerent
biological and pathological behavior48,49 because they suggest
that tau induced to aggregate by polyanions may not
recapitulate adequately the structure of tau found in patient
brains. In addition, the use of artiﬁcial aggregation inducers
complicates the interpretation of experiments testing assembly
modulators and inhibitors as potential therapeutic agents for
tauopathies. An alternative approach is to produce in vitro
phosphorylated tau for studies of aggregation, structure,
pathological eﬀects, and modulation of all of these processes.
However, to date, only a few studies have used this strategy,
and their focus was on the ﬁbril formation and morphol-
ogy.30,50,51 To our knowledge, tau oligomerization, the seeding
activity of tau, and the inhibition of aggregation or seeding
have not been studied using in vitro phosphorylated
recombinant tau to date.
As a test modulator, we chose in this study the molecular
tweezer CLR01. Molecular tweezers are broad-spectrum
modulators of the aberrant self-assembly process of amyloid
proteins.52,53 They act by moderate, labile binding to Lys, and
to a lower extent to Arg residues through inclusion of the side
chain in the cavity of the molecular tweezer, which leads to
temporary masking of hydrophobic interactions in which these
side chains participate and reversal of the positive charge of
their end groups to a negative charge. This causes major
perturbation of interactions involving Lys (or Arg), which play
an important role in the abnormal self-assembly of
amyloidogenic proteins. A lead molecular tweezer called
CLR01, substituted by two negatively charged phosphate
groups at the central benzene spacer-unit (Figure 4A), has
been shown to modulate the oligomerization and aggregation
of over a dozen disease-associated amyloidogenic proteins and
to be an eﬀective inhibitor of the toxicity of these proteins in
cell culture and animal models of the associated diseases.52,53
However, relatively little is known about the interaction of
molecular tweezers with tau.
Here, we conducted a systematic investigation of tau
oligomerization, aggregation, and seeding, comparing hep-
arin-induced tau with two forms of in vitro phosphorylated tau.
We also tested how CLR01 interacted with each tau form and
characterized the binding sites of CLR01 on tau. Our data
suggest that the oligomerization and aggregation kinetics of
heparin-induced tau are diﬀerent from those of in vitro
phosphorylated tau and that these diﬀerent forms lead to
diﬀerent tau strains that can be detected in biosensor cells, as
described previously for brain-derived tau aggregates support-
ing the notion that these forms of tau ﬁbrils are structurally
distinct.54 CLR01 interacts preferentially with Lys residues
located in the MTBD and ﬂanking regions and phosphor-
ylation of tau has little eﬀect on this interaction. CLR01
modulates the aggregation and seeding of the diﬀerent forms of
tau; yet, in most experiments, the dose−response relationship
of CLR01 with heparin-induced tau and in vitro phosphory-
lated tau is diﬀerent, supporting the notion that these forms of
tau ﬁbrils are distinct and suggesting that heparin induction
interferes with the interaction of CLR01 with tau.
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■ RESULTS
Comparison of Heparin-Induced and in Vitro
Phosphorylated Tau Self-Assembly. To establish baseline
conditions for comparison of in vitro phosphorylated tau with
heparin-induced tau, we incubated a mixture of 5 μM tau and
1.25 μM heparin at 37 °C and measured ThT ﬂuorescence up
to 100 h. As expected, we observed a typical sigmoidal increase
in ThT ﬂuorescence, beginning with a short lag phase (∼30
min), followed by a sharp increase in ﬂuorescence over the
next 6 h and then a slower increase up to a plateau at ∼12 h
(Figure 1A). We derived the aggregation rate constant, k, by
ﬁtting the kinetic curves to a one-phase association equation
(eq 1). Under these conditions, k was found to be 0.29 ± 0.02
h−1. Examination of the morphology at the end of the reaction
by TEM showed abundant, relatively short ﬁbrils (Figure 1B).
Despite site-speciﬁc, high-level phosphorylation at several
sites, tau phosphorylated by ERK (p-tauERK) has been reported
previously not to produce a detectable increase of the ThT
ﬂuorescence signal.29,30 In agreement with these previous
observations, solutions of 100 μM p-tauERK did not aggregate
up to 100 h (Figure 1A). TEM examination showed only
nonﬁbrillar, amorphous aggregates (Figure 1C) as observed
previously.29,30
The quantitative phosphorylation pattern of tau phosphory-
lated by a whole rat brain extract (RBE, p-tauRBE), as
determined by NMR, has been reported to be similar to that
of p-tauERK, but contains three additional phosphorylation
sitesat S208 in the PRR, and at S262 and S356 in the
MTBD (Table 1).29 Because phosphorylation of S262 is
known to inhibit tau aggregation,28 S262 was substituted by
Ala for generation of p-tau(S262A)RBE to prevent phosphor-
ylation at this site. At 5−10 μM, the aggregation of p-
tau(S262A)RBE was too slow to compare side-by-side with
heparin-induced tau. However, at 30 μM, p-tau(S262A)RBE
reactions showed a sigmoidal increase in ThT ﬂuorescence,
beginning with a short lag phase of ∼1 h, followed by an
increase in ﬂuorescence over 45 h to reach a plateau. Despite
using a higher concentration, the aggregation kinetics of p-
tau(S262A)RBE was substantially slower than that of heparin-
induced unphosphorylated tau (Figure 1A). The rate constant,
k, in this case was 0.066 ± 0.001 h−1. Examination of the ﬁbril
morphology at the end of the reaction by TEM showed
Figure 1. Self-assembly of tau induced by heparin, p-tauERK and p-tau(S262A)RBE. (A) Time-dependent ThT ﬂuorescence of 5 μM heparin-induced
tau, 100 μM p-tauERK, or 30 μM p-tau(S262A)RBE. (B−D) Morphological examination by TEM at the end of the aggregation reaction (t = 100 h)
of heparin-induced tau (B), p-tauERK (C) and p-tau(S262A)RBE (D). (E) Native PAGE analysis of 10 μM each of heparin (hep)-induced tau, p-
tauERK, and p-tau(S262A)RBE at t = 0, 10, or 20 h of incubation under the same conditions. For heparin-induced tau, t = 0 is immediately after
addition of heparin. Molecular weight markers are shown on the left. The mobilities of putative monomer (M), dimer (D), trimer (Tr), and
tetramer (Te) are indicated on the right.
Table 1. Tau Variants Used in This Study
tau proteins residues phosphorylation sites
F4 208−324
tau 1−441
p-tauERK 1−441 S46, T50, T69, T153, T175, T181, S191,
S199, S202, T205, T231, S235, S396,
S404, S422
p-tau(S262A)RBE 1−441,
S262A
S46, T50, T69, T153, T175, T181, S191,
S199, S202, T205, S208, T231, S235,
S356, S396, S404, S422
aThe underlined residues correspond to phosphorylation sites
uniquely found using the kinase activity in the rat brain extract.
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abundant ﬁbrils, which were thicker and longer than those of
heparin-induced tau (Figure 1D, Supplementary Figure S1). As
shown previously,30 the ﬁbrils had both straight and squiggly
morphology but did not show a helical twist (Supplementary
Figure S1).
We asked next whether intermediate oligomers forming
during the aggregation process could be detected and how they
compared among the three forms of tau. We addressed this
question by analyzing aliquots from aggregation mixtures
containing 10 μM of each tau form at 0, 10, and 20 h using
native PAGE/Western blot probed with the antihuman tau
mAb HT7. Interestingly, we found a distinct behavior for each
form (Figure 1E). At t = 0 h, i.e., just after addition of heparin
to unphosphorylated tau, the protein appeared as a smear over
nearly the entire length of the gel. A band at ∼70 kDa,
presumably a monomer, could be discerned, as well as a lower
band, at ∼60 kDa, likely representing a truncation/degradation
product. At t = 10 h, most of the protein seemed to
“disappear,” likely due to aggregation preventing it from
entering the gel, and only relatively faint smears with apparent
mobility corresponding to 140−1000 kDa were observed. At t
= 20 h relatively little protein was apparent, suggesting further
aggregation. At this time point, possibly due to the relatively
low amount of apparent protein, faint smeary bands
corresponding to putative monomer through tetramer were
observed.
In agreement with the lack of observed ﬁbril formation in
the case of p-tauERK, this protein showed several bands,
including putative monomer through tetramer, a higher
molecular weight smear at 800−1000 kDa, and a band at
∼1100 kDa, likely a high-molecular-weight oligomer. At 10 and
20 h, the putative trimer, tetramer, and high-molecular-weight
smear at 800−1000 kDa seemed to convert to the high-
molecular-weight oligomer at ∼1100 kDa, whereas little or no
change was observed in the putative monomer and dimer
abundance.
The behavior of p-tau(S262A)RBE, which unlike p-tauERK did
form β-sheet-rich ﬁbrils, was more similar to that of heparin-
induced unphosphorylated tau than to p-tauERK. At t = 0 h, the
appearance was smeary with discernible putative monomer and
dimer bands that migrated slightly slower than their
unphosphorylated counterparts, whereas at 10 and 20 h,
most of the signal gradually disappeared and lower molecular
weight species appeared more abundant at 20 h than at 10 h.
In all cases, the solutions/suspensions were mixed thoroughly
before loading on the gel to ensure that potential ﬁbrils/
aggregates precipitated at the bottom of the tube would be
included. However, these large species apparently were too
large to enter the gel and therefore were not observed.
Alternatively, they may have been present but did not react
with HT7.
Comparison of Heparin-Induced and in Vitro
Phosphorylated Tau Seeding in Biosensor Cells. Toxic
tau species are thought to pass from aﬀected cells to
synaptically connected unaﬀected cells, where the seeds serve
as templates that corrupt normal tau proteins and cause them
to aggregate.62,63 To facilitate characterization of the seeds,
Diamond’s group has developed biosensor cells that allow
detecting and quantifying tau seeding using a sensitive
ﬂuorescence-resonance energy transfer (FRET) assay.64 The
assay has been shown to have a wide dynamic range, allowing
comparison of samples with vastly diﬀerent levels of tau
seeding and distinguishing among samples showing subtle
diﬀerences.63
Here, we used this assay to compare the seeding capability of
the three tau variants. We began with testing the seeding
activity of ﬁbrils formed by heparin-induced tau or p-
tau(S262A)RBE, which were sheered by sonication for 10 min
and mixed with the transfection agent, lipofectamine, for
eﬀective transduction into the biosensor cells, as described
previously.64 We examined the cells qualitatively by
ﬂuorescence microscopy for the presence of observable puncta
and quantitatively for the CFP−YFP FRET signal using ﬂow
cytometry.
In untreated cells, only diﬀuse ﬂuorescence was observed
(Figure 2A), whereas bright puncta were detected following
addition of either type of ﬁbrils (Figure 2B,C) indicating
seeding of tau aggregation. Quantitative analysis by ﬂow
cytometry showed that both forms induced a robust seeding
response. The magnitude of the response was higher overall for
heparin-induced tau, though the diﬀerence reached statistical
signiﬁcance only at the highest concentration (1 μM, Figure
2D). Interestingly, high-magniﬁcation examination revealed
distinct morphology and localization of the aggregates.
Aggregates induced by heparin-induced tau were larger and
mainly cytosolic or perinuclear (Figure 2E), whereas those
induced by p-tau(S262A)RBE were smaller and colocalized with
nuclei. These observations suggest that although both forms of
tau form ThT-positive ﬁbrils the arrangements of the tau
molecules in these ﬁbrils are diﬀerent and represent distinct
strains based on their seeding activity and aggregate
morphology in the biosensor cells.
Because previously both tau ﬁbrils and oligomers as small as
a trimer were shown to act as seeds,64 we tested also whether
the three tau variants could seed tau aggregation immediately
after dissolution, when presumably only monomers and
Figure 2. Induction of tau seeding by aggregated tau in biosensor
cells. (A−C) Fluorescence microscopy images of tau biosensor cells.
(A) Negative control cells incubated with media alone. (B) Cells
incubated with heparin-induced tau ﬁbrils. (C) Cells incubated with
p-tau(S262A)RBE ﬁbrils. (D) Dose−response analysis of the seeding
activity (integrated FRET density) of each tau form. (E, F) High-
magniﬁcation ﬂuorescence microscopy images of cells incubated with
1 μM of either heparin-induced tau ﬁbrils (E) or p-tau(S262A)RBE
ﬁbrils (F). Bright YFP ﬂuorescence indicates tau aggregates. Nuclei
were stained with 4′,6-diamidino-2-phenylindole (DAPI, blue).
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putative oligomers are present. Cells treated with freshly
dissolved unphosphorylated tau in the absence (Figure 3A) or
presence of heparin (Figure 3B) did not show formation of
puncta. The latter condition produced a minimal FRET signal
(Figure 3E). In contrast, freshly dissolved 1-μM p-tauERK
showed abundant bright puncta (Figure 3C) and induced a
strong, dose-dependent seeding response (Figure 3E).
Similarly, freshly dissolved 1-μM p-tau(S262A)RBE promoted
formation of bright puncta (Figure 3D) and caused dose-
dependent tau aggregation in the biosensor cells, albeit slightly
weaker than p-tauERK (Figure 3E). Overall, the seeding activity
of the freshly dissolved phosphorylated tau proteins was ∼4-
fold weaker than that of the ﬁbrils (cf. Figures 2D and 3E).
These data suggested that unlike unphosphorylated tau, p-
tauERK and p-tau(S262A)RBE contained seed-competent tau
monomers or preformed seeds, or formed seeds, presumably
oligomers, during the experiment.65 High-resolution images
showed that the aggregate morphology and localization of
freshly dissolved p-tauERK (Figure 3F) and p-tau(S262A)RBE
(Figure 3G) resembled those of ﬁbrillar p-tau(S262A)RBE
(Figure 2F), i.e., were small relative to the cell body and
colocalized partially with nuclei, but not of heparin-induced tau
ﬁbrils (Figure 2E).
Formation of a small population of aberrant, cross-linked tau
dimers via an intermolecular disulﬁde bond has been reported
previously to promote seeding by the FTD-linked P301L tau
isoform.66 To test whether the seeding in our experiments was
due to formation of disulﬁde-cross-linked dimers (or other
oligomers), we reduced the protein by addition of 6-fold excess
DTT and repeated the seeding measurements. The ﬁnal
concentration of DTT in the cell culture media, 6 μM, did not
cause any apparent change to the cells’ morphology or viability.
The measurements did not show signiﬁcant diﬀerences
between the seeding of either tau variant in the presence of
DTT (Figure 3E), suggesting that aberrant intermolecular
disulﬁde-mediated oligomerization did not contribute to the
observed seeding.
Taken together, the results suggest that unphosphorylated
tau needs to be induced to form ﬁbrils in order to become
seeding-competent. In contrast, in vitro phosphorylated tau is
seeding-competent already when freshly dissolved, presumably
due to the presence of oligomers (Figure 1E). However, upon
ﬁbril formation, the seeding activity of p-tau(S262A)RBE
increases by ∼4-fold. p-tauERK and p-tau(S262A)RBE appear
to form a similar strain, which is diﬀerent from the one formed
by heparin-induced tau. The strain formed by p-tau(S262A)RBE
seems to be maintained in both the freshly dissolved and
ﬁbrillar states.
CLR01 Inhibits the Aggregation of Heparin-Induced
and in Vitro Phosphorylated Tau with Distinct Dose-
Dependencies. Similar to anionic aggregation inducers, such
as heparin or arachidonic acid, CLR01 (Figure 4A) binds to
positively charged residues in tau. This competition for the
same binding sites makes data interpretation diﬃcult because
CLR01 binding could inhibit tau aggregation by two
independent mechanisms: (1) competition with the inducer
for the Lys/Arg residues, thereby attenuating the induction of
tau aggregation; and (2) direct interference with intermolec-
ular interactions among tau molecules. Therefore, we sought to
distinguish between these two mechanisms and to compare
between this nonideal system and a simpler system in which
CLR01 interacts with phosphorylated tau.
To determine the extent to which CLR01 competes with
heparin for tau binding, we used SPR. Heparin was
immobilized on a SPR chip, and tau binding to the
immobilized heparin was found to occur with KD = 10.9 nM
(Figure 4B), in agreement with recent results obtained using
ELISA.67 Similar experiments using solutions in which tau was
mixed with CLR01 at diﬀerent ratios then were performed,
with the expectation that when the heparin binding sites in tau
are occupied by CLR01, tau binding to the surface-
immobilized heparin should decrease, resulting in a reduction
in the magnitude of the SPR signal. This well-established
method has been used previously for characterizing heparin−
protein interaction.68,69 The analysis showed that CLR01
competed with heparin for binding to tau (Figure 4C) but, in
agreement with its highly labile binding, was a relatively weak
competitor. The IC50 for the inhibition of 0.5 μM tau binding
to immobilized heparin by CLR01 was found to be 20 ± 1 μM
(Figure 4D); i.e., 40-fold excess CLR01 relative to tau was
needed for half-maximal inhibition.
Next, to test the eﬀect of CLR01 on heparin-induced
aggregation of tau, the unphosphorylated protein was
incubated at 5 μM in the presence of 1.25 μM heparin, and
CLR01 was added at concentrations ranging from 2.5 to 40
μM. CLR01 caused a dose-dependent decrease in the
Figure 3. Induction of tau seeding by freshly dissolved tau in
biosensor cells. (A−D) Fluorescence microscopy images of tau
biosensor cells incubated with 1 μM freshly dissolved tau (A), tau +
heparin (B), p-tauERK (C), or p-tau(S262A)RBE (D). (E) Dose−
response analysis of the seeding activity (integrated FRET density) of
each tau form in the absence or presence of DTT. (F, G) High-
magniﬁcation ﬂuorescence microscopy images of cells incubated with
300 nM freshly dissolved p-tauERK (F) or p-tau(S262A)RBE (G).
Bright YFP ﬂuorescence indicates tau aggregates. Nuclei were stained
with DAPI (blue).
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aggregation rate constant, k, and inhibited the aggregation
completely at 6-fold excess (Figure 5A). A plot of percentage
of inhibition (calculated using eq 2) versus [CLR01] showed
that the molecular tweezer inhibited the aggregation of
heparin-induced tau with a half-maximal inhibitory concen-
tration (IC50) of 11.3 ± 0.6 μM (Figure 5B). Considering that
both primary and secondary nucleation events may aﬀect tau
aggregation, we also attempted to use the method of Cohen et
al.,70,71 which takes into account both nucleation mechanisms.
We found little or no contribution of secondary nucleation,
minimal changes in the data ﬁtting, and a nearly identical IC50
value, 11.8 ± 0.7 μM, using this method. Because inhibition of
aggregation does not always produce the same eﬀect on the
slope of the ThT curve and the ﬁnal plateau value, we
calculated an IC50 value also based on the ﬁnal plateau and
found it to be in the same range, 19 ± 0.6 μM (Supplementary
Figure S2A). In this experiment, only 2−3-fold excess CLR01
was suﬃcient for half-maximal inhibition, as opposed to the
40-fold excess needed for half-maximal inhibition of tau
binding to heparin. Therefore, we conclude that the main
inhibitory eﬀect of CLR01 on tau aggregation is mediated by
direct interference with tau self-assembly rather than by
inhibition of heparin binding.
Because of the diﬀerent aggregation kinetics of heparin-
induced tau and p-tau(S262A)RBE (Figure 1A), side-by-side
comparison at the same concentration was not practical. Thus,
to measure the eﬀect of CLR01 on the aggregation of p-
tau(S262A)RBE, the protein was incubated at 30 μM in the
presence of increasing CLR01 concentrations. Interestingly, at
substoichiometric concentrations, CLR01 appeared to have a
mixed eﬀect on the aggregation kinetics of p-tau(S262A)RBE
initially, the kinetics was accelerated, whereas after ∼24 h, the
aggregation rate was reduced compared to reactions in the
absence of CLR01 (Figure 5C). In contrast, at 2- or 4-fold
excess, CLR01 inhibited the aggregation completely (Figure
5C,D and Supplementary Figure S2B). These results further
demonstrate that heparin-induced tau aggregation is dissimilar
to the aggregation of hyperphosphorylated tau and in
particular may yield misleading results when analyzing
aggregation modulators, such as CLR01.
ThT ﬂuorescence measures the formation of the cross-β
structure when amyloidogenic proteins aggregate, but the
increase in ThT ﬂuorescence does not always correlate with
ﬁbril formation.72−74 To assess whether in this case the initial
acceleration in β-sheet formation reﬂected formation of ﬁbrils,
we examined the morphology of each preparation at the end of
the aggregation reaction by TEM. The morphological
examination showed that addition of CLR01 resulted in a
dose-dependent inhibition of ﬁbril formation by both heparin-
induced tau and p-tau(S262A)RBE (Figure 6, Supplementary
Figure S3). In the case of heparin-induced tau, thin, straight or
squiggly ﬁbrils could still be observed up to a tau/CLR01
concentration ratio of 1:4, respectively, whereas at higher
concentrations the morphology was amorphous (Supplemen-
tary Figure 3A). Fibrils of p-tau(S262A)RBE were substantially
reduced at a p-tau(S262A)RBE/CLR01 concentration ratio
1:0.25 and eliminated at a concentration ratio of 1:0.5 or
higher (Supplementary Figure 3B), demonstrating that the
acceleration of the ThT ﬂuorescence increase at substoichio-
metric CLR01 concentrations did not reﬂect ﬁbril formation.
These data are in agreement with an increase in ThT
ﬂuorescence without ﬁbril formation by other proteins in the
presence of CLR01;75,76 yet the nature of the early ThT-
positive structures forming in the presence of CLR01 is not
well-understood.
CLR01 Inhibits Tau Seeding in Biosensor Cells. Next,
we asked whether CLR01 could inhibit the seeding activity of
tau ﬁbrils. To answer the question, we incubated the cells with
CLR01 concentrations ranging from 10 nM to 50 μM for 16 h
to allow uptake of the molecular tweezer into the cells. Then,
we added 150 nM heparin-induced tau or p-tau(S262A)RBE
ﬁbrils, which had been sonicated for 10 min prior to addition
to the cells and measured the seeding activity after additional
24 h of incubation.
The seeding activity of heparin-induced tau ﬁbrils was again
higher than that of p-tau(S262A)RBE (Figure 7A). Confocal
microscopy conﬁrmed the formation of abundant seeds in cells
treated only with heparin-induced tau ﬁbrils and not with
CLR01 (Figure 7B), whereas no seeds could be seen in cells
incubated with CLR01 prior to addition of tau seeds (Figure
7C). The presence of CLR01 in cells treated with heparin-
induced tau up to a 1:1 tau/CLR01 concentration ratio,
respectively, increased the seeding activity compared to cells
treated with the same seeds in the absence of CLR01, whereas
at higher concentrations, CLR01 inhibited tau seeding. In
contrast to the mixed eﬀect of CLR01 on the seeding of
heparin-induced tau ﬁbrils, the molecular tweezer inhibited the
seeding of p-tau(S262A)RBE seeds dose-dependently with IC50
= 660 ± 140 nM (Figure 7A), further demonstrating the
distinct behavior of the two types of tau aggregates and the
problematic nature of using heparin-induced tau aggregates for
testing aggregation and/or seeding modulators, such as
CLR01.
A potential concern with interpretation of this experiment is
that CLR01 could act directly on the seeds themselves and
induce their dissociation once they get internalized by the
biosensor cells. However, the labile binding of CLR01 would
Figure 4. Inhibition of tau binding to heparin by CLR01. Binding of
tau to immobilized heparin and its inhibition by CLR01 were
measured using SPR. (A) A schematic structure of CLR01. The
compound is partially protonated at physiologic pH. (B) SPR
sensorgram of tau binding to heparin immobilized on a SPR chip. (C)
Normalized tau binding in the presence of increasing concentrations
of CLR01. (D) % Inhibition versus CLR01 concentration used for
calculating the half-maximal inhibition (IC50).
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not be expected to aﬀect such ﬁbrils, unless they are incubated
with a large excess of the molecular tweezer for long periods, as
has been shown previously for other amyloidogenic pro-
teins.75,77,78 Indeed, morphological examination showed that
when tau ﬁbrils were incubated with CLR01 for 24 h in vitro,
CLR01 did not cause appreciable changes in the ﬁbril structure
(Supplementary Figure S4).
NMR-Based Mapping of CLR01 Binding to the
Diﬀerent Tau Variants. To gain further insight into the
way CLR01 interacts with tau, we used solution-state NMR.
Full-length tau contains 44 Lys residues, each of which is a
potential binding site for CLR01. However, the aﬃnity of
CLR01 for each Lys residue depends both on the ﬂanking
amino acid sequences and on the local and global
conformation. Lys residues also are binding sites for
heparin.42,79,80 Previous NMR mapping of tau−heparin
interaction revealed that large heparins bind to most of the
Lys residues in the MTBD and PRR, and to a low extent also
to Lys residues in the extreme N-terminus.81 Using small
heparins, speciﬁc hotspots have been identiﬁed allowing
discrimination between sites with diﬀerent binding aﬃnities.42
Because binding of either CLR01 or heparin would be
expected to cause perturbation of Lys residues, we did not
attempt to use NMR for the characterization of the
competition between the two molecules for binding to tau.
Rather, we used NMR to determine whether phosphorylation
alters the binding of CLR01 to tau.
Unlike heparin, CLR01 binds one Lys residue at a time by
including the Lys side chain inside the cavity of the molecular
tweezer, thus forming hydrophobic interactions with the
tweezer’s “arms” and electrostatic interactions between the ε-
NH3
+ group of Lys and the phosphate groups of the molecular
tweezer. As CLR01 is a symmetric compound containing two
phosphate groups, if another positively charged residue, such
as Lys or Arg is nearby, it could form additional electrostatic
interactions with the second phosphate group of CLR01, but
those would be substantially weaker because only one Lys side
chain can be included inside the cavity. Given this binding
mode, we asked ﬁrst if CLR01 had a preference for selective
binding to certain Lys residues versus others. CLR01 also
binds to Arg residues, but with 5−10-times lower aﬃnity than
to Lys residues.55,82,83 Therefore, we focused most of our
Figure 5. Inhibition of tau aggregation by CLR01. (A) Time-dependent ThT ﬂuorescence in aggregation reactions containing 5 μM tau, 1.25 μM
heparin, and increasing concentrations of CLR01 showing replicates and ﬁtted association curves. (B) Dose−response analysis of the ﬂuorescence
data in panel A was calculated by extracting the kinetic constant k from ﬁtted curves and normalizing to k0, the kinetic constant in the absence of
CLR01. (C) Time-dependent ThT ﬂuorescence in aggregation reactions containing 30 μM p-tau(S262A)RBE and increasing concentrations of
CLR01 showing replicates and ﬁtted association curves. “Tau-S262A” is a negative control containing this variant of tau in an unphosphorylated
form. (D) Dose−response analysis of the ﬂuorescence data in panel C was calculated by extracting the kinetic constant k from ﬁtted curves and
normalizing to k0, the kinetic constant in the absence of CLR01.
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analysis on Lys only using selective 15N-Lys labeling of tau,
which helps reducing signal crowding in two-dimensional
1H−15N HSQC spectra. The assignment of Lys resonances in
the 1H−15N HSQC spectrum of 15N-Lys-labeled tau has been
described previously.42,81
We analyzed unphosphorylated tau ﬁrst to establish a
baseline. We titrated 200 μM 15Nα,ε-Lys-labeled tau with
increasing concentrations of CLR01 ranging from 20 to 400
μM and recorded a 1H−15N HSQC spectrum for each titration
point. As the concentration of CLR01 increased, we observed
minimal chemical shift variations, but the HSQC signal
intensity decreased gradually (Figure 8A; Supplementary
Figure S5). Because of the dynamic nature of its on−oﬀ
exchange, CLR01 binding induces a severe broadening of Lys
resonances associated with signal intensity decrease, as has
been reported previously in Aβ.75 We observed a similar
behavior in a short peptide derived from tau (data not shown).
In 1H spectra, we observed a substantial decrease in 1H
resonance intensities of aliphatic protons in Lys residues,
whereas other 1H resonances decreased only by <5% at the
highest concentration of CLR01 (Figure 8B), conﬁrming
speciﬁc interactions of CLR01 with Lys residues. For example,
∼50% of the Lys Hε signal at 2.99 ppm disappeared at the
highest tau/CLR01 ratio 1:2, respectively (Figure 8B). At this
ratio, the CLR01/Lys ratio is 1:22. Thus, the strong decrease
in the overall signal of Lys demonstrates the fast on−oﬀ rate of
CLR01 binding to Lys. Interactions of CLR01 with more than
one Lys residues at a time, leading to further signal broadening,
also could account for the large signal decrease at low CLR01/
Lys ratios.
Mapping of the resonance intensity variations using the two-
dimensional 1H−15N HSQC spectra indicated that CLR01
bound preferentially to Lys residues in the MTBD and to a
lower extent in the PRR. Most of the binding occurred in the
region between K224 and K395 with the exception of K130 for
which strong binding was found. Interestingly, little binding
was detected to the Lys residues at the N- and C-termini
(Figure 8C). A possible explanation for this preference is that
the extreme N- and C-terminal regions are more acidic than
the remaining of the protein (Supplementary Figure S6),
which may lead to electrostatic repulsion of the negatively
charged CLR01.
To gain additional insight into the binding of CLR01 within
its main region of interaction in tau, we mapped its binding on
the fragment F4, which encompasses residues 208−324
(Figure 8D and Supplementary Figure S5). F4 maintains
many of the physiologic and pathologic functions of full-length
tau, e.g., microtubule binding and the capacity to form PHF-
like ﬁbrils.84,85 F4 was produced with uniform 15N-labeling
allowing mapping of intensity changes for all the residues of
the fragment. The titration was performed using the same
increasing concentrations of CLR01 and under the same
conditions used for full-length tau. F4 contains 17 of the 44
Lys residues of full-length tau, out of a total of 117 residues
(i.e., Lys residues comprise 14.5% of the F4 sequence,
compared to 10% of full-length tau) and 5 Arg residues
(4.3% of the F4 sequence) all located in the PRR, at positions
209, 211, 221, 230, and 242. R209 and R211 were not detected
in the HSQC spectrum, and only low-intensity variations,
between 12% and 25% intensity loss, were observed for the
other three Arg residues (Figure 8D) indicating weak binding
of CLR01 to these Arg residues, in line with data described
previously.55,82,83
A gradual intensity loss was observed for some, but not all of
the Lys residues (Figure 8D). Residues in the extreme N-
terminus, e.g., S210, which was conjugated to a (His)6-tag, and
His residues, e.g., H268 in the F4 sequence, showed substantial
intensity changes, which likely reﬂected the high sensitivity of
the His signal to small pH variations rather than CLR01
binding. Previously, the aﬃnity of CLR01 for His was
determined to be only ∼10% of the aﬃnity for Lys.55
Except for these residues, K224, K225, K240, K259, and
K280 showed substantial intensity decrease, up to 50%, at
equimolar concentration of CLR01 (Figure 8D). The most
pronounced intensity decrease, 60 and 80%, respectively, was
found for K290 and K321, both within KCGS motifs.
However, it is diﬃcult to determine whether this strong
decrease represents the high sensitivity of Cys residues to
changes in the environment or an actual higher aﬃnity of
Figure 6. Representative TEM images taken at the end of the
aggregation reactions shown in Figure 5. (A) Images of 5 μM heparin-
induced tau in the absence or presence of the indicated tau/CLR01
concentration ratios. (B) Images of 30 μM p-tau(S262A)RBE in the
absence or presence of the indicated p-tau(S262A)RBE/CLR01
concentration ratios.
Figure 7. CLR01 inhibits tau seeding in biosensor cells. Cells were
incubated for 16 h in the absence or presence of increasing CLR01
concentrations, followed by addition of seeds. After additional 24 h of
incubation, seeding was visualized by ﬂuorescence microscopy and
quantiﬁed using ﬂow cytometry. (A) Dose−response analysis of the
seeding activity (integrated FRET density) of each tau form in the
absence or presence of CLR01. (B, C) High-magniﬁcation
ﬂuorescence microscopy images of cells incubated with heparin-
induced tau ﬁbrils after pretreatment with media alone (B) or 50 μM
CLR01 (C). Bright YFP ﬂuorescence indicates tau aggregates. Nuclei
were stained with DAPI (blue).
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CLR01 for the Lys residues in these positions. The data are in
good agreement with a recent report, which found using top-
down mass spectrometry that a primary binding site for CLR01
in full-length tau was in a segment spanning residues K294−
K331.86 Importantly, Lys residues in F4 showed a comparable
intensity decrease to their counterparts in full-length tau at the
same protein/CLR01 concentration ratios (Supplementary
Figure S5C), suggesting that the changes reﬂected the genuine
aﬃnity of CLR01 for these particular Lys residues.
After establishing the main binding region and speciﬁc
primary binding sites of CLR01 on unphosphorylated tau, we
asked how phosphorylation might aﬀect CLR01 binding. We
investigated the binding of CLR01 to p-tauERK and p-
tau(S262A)RBE by NMR in a manner similar to the
unphosphorylated protein. First, we performed experiments
using uniformly 15N,13C-labeled tau and selectively 15Nα,ε/
13C-
Lys,13C-labeled p-tauERK, to determine the phosphorylation
pattern (Supplementary Figures S7 and S8) and facilitate the
mapping of resonance intensity upon CLR01 titration, to
determine the phosphorylation pattern (Supplementary Figure
S7). The ﬁndings are summarized in Table 1.
Spectral heterogeneity occurs upon incomplete phosphor-
ylation of several Ser/Thr residues leading to a splitting of
protein resonances for the phosphorylation sites and
surrounding residues. Assignment of 1H−15N resonances of
15Nα,ε/
13C-Lys,13C-labeled p-tauERK was performed using a
three-dimensional HN(CO)CACB experiment, which allows
assigning Lys resonances that shift upon phosphorylation due
to their proximity to phosphorylation sites (Supplementary
Figure S7). Examination of the 1H−15N HSQC NMR spectra
of Lys-labeled p-tauERK revealed distinct behavior of certain
Lys resonances. Some Lys resonances were split into two or
more peaks due to phosphorylation heterogeneity, including
K67, K190, K224, K225, and K234, and low-intensity
resonances of the nonphosphorylated form were still detected.
In contrast, for K44, K150, K174, K180, K240, and K395, only
peaks corresponding to the phosphorylated state were
detected, as shown for K240, Figure 9A,B, indicating a high
phosphorylation level for sites in the vicinity of these Lys
residues (Supplementary Figure S7, Table 1).
The resonance intensity changes upon CLR01 binding to p-
tauERK (Figure 9C) suggested that phosphorylation had only a
minor eﬀect on the binding. The binding pattern of CLR01 to
p-tauERK resembled the binding to unphosphorylated tau,
targeting primarily the MTBD and to a lesser extent the
ﬂanking regions (Figure 9C and Supplementary Figure S9).
Figure 8. NMR mapping of CLR01 binding to tau and F4. (A) NMR mapping of 15N-Lys-labeled tau in the absence (black spectrum) or presence
(blue spectrum) of a 2-fold excess CLR01. (B) 1H spectra of 15N-Lys-labeled tau with increasing concentration of CLR01. The Hε resonance of Lys
side chains at 2.99 ppm is depicted in the inset showing a selective decrease of 1H signals of Lys residues. A similar intensity decrease was found for
Lys Hδ resonances at 1.65 ppm. (C, D) Mapping of resonance intensity of Lys residues along the
15N-Lys-tau (C) or 15N−F4 (D) sequences for
diﬀerent protein/CLR01 ratios. The region in gray in (C) corresponds to the F4 sequence.
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Only binding to the PRR was slightly reduced (Supplementary
Figures S9 and S10). This observation was consistent with the
location of most of CLR01’s binding sites in the MTBD, as
opposed to most of the phosphorylation sites in the PRR and
the extreme N- and C-termini. The only exceptions were K150,
K174, and K240, which are adjacent to the phosphorylation
sites T153, T175, and T231/S235, respectively. Binding of
CLR01 to these three Lys residues was signiﬁcantly reduced
upon phosphorylation (Figure 9C,D and Supplementary
Figures S9 and S10).
The binding sites found for CLR01 on p-tau(S262A)RBE
were similar to those in unphosphorylated tau and p-tauERK
(Supplementary Figures S9 and S10). Together, these data
indicate that tau phosphorylation does not aﬀect CLR01
binding substantially, allowing the molecular tweezer to remain
an eﬀective inhibitor of tau aggregation, oligomerization, and
seeding.
■ DISCUSSION
In Alzheimer’s disease and other tauopathies, aberrant post-
translational modiﬁcation of tau leads to its self-assembly into
neurotoxic oligomers and ﬁbrils. Of the PTMs studied to date,
hyperphosphorylation has been found most frequently and
likely is the main PTM instigating aberrant tau self-assembly.
The requirement of post-translational modiﬁcations for
induction of aggregation makes studying this process in vitro
or in cell culture diﬃcult. To create experimental systems
allowing such studies, researchers long have been using heparin
and other polyanions to induce tau aggregation. These artiﬁcial
models are particularly convenient for screening tau
aggregation inhibitors and disaggregation inducers;87 yet,
concerns about the artiﬁcial nature of such systems, and in
particular about potential interference by the polyanions with
testing potential modulators and inhibitors of aberrant tau self-
assembly, have been increasing. Recently, cryo-EM structures
showed that heparin-induced 4R and 3R tau ﬁbrils are
structurally distinct from those in Alzheimer’s and Pick’s
disease questioning the relevance of such in vitro assays.88
Furthermore, Fichou et al. have reported that heparin and
RNA used to induce ﬁbril formation coassemble with tau in
vitro.47 Heparin-induced tau ﬁbrils used in in vitro seeding
assays seeded freshly dissolved tau only in the presence of
RNA, whereas mouse-brain-derived tau ﬁbrils could be used as
seeds in the absence of cofactors in the ﬁrst-generation seeding
reaction and required RNA as a cofactor to increase the
seeding activity of the second-generation reaction. On the basis
of these ﬁndings, they suggested that in vivo, an unknown
cofactor might be necessary for tau aggregation. Our data
suggest that such cofactors are not necessary for tau ﬁbrillation
and that hyperphosphorylation of tau is suﬃcient for induction
of ﬁbril formation. In view of recent advances in generating in
vitro phosphorylated tau,29,30 here we set out to compare side-
by-side this newer form of aggregation-prone tau with the
common method of tau induced to aggregate by addition of
heparin.
Induction of tau aggregation by addition of heparin allowed
using a lower concentration of the protein and resulted in
faster aggregation kinetics than those measured using p-
tau(S262A)RBE (Figure 1A). The morphology of the resulting
ﬁbrils was diﬀerentp-tau(S262A)RBE ﬁbrils were both thicker
and longer than those of heparin-induced tau (cf. Figure 1,
panels B and D), demonstrating that the two forms were
structurally distinct.
Figure 9. Binding site analysis of CLR01 on p-tauERK. (A, B) Superimposition of 1H−15N HSQC spectra of selectively 15N-Lys-labeled p-tauERK
(A) and unphosphorylated tau (B) at 200 μM in the absence (black) or presence of 200 μM CLR01 (blue). Resonances of K240 corresponding to
phosphorylated forms in panel A are annotated by K240−P1 and K240−P2. Note that the unphosphorylated form of K240 shown in panel B is
absent in p-tauERK. The location of this missing resonance is indicated in panel A by “x”. (C) Variation of K240 resonance intensity upon increasing
CLR01 concentrations for the unphosphorylated form in tau (open squares) and both phosphorylated forms in p-tauERK shown in panel A (ﬁlled
diamonds and triangles). (D) Changes in resonance intensity of Lys signals in p-tauERK upon CLR01 binding for protein/CLR01 ratios ranging
from 1:0.1 to 1:2. For Lys residues close to phosphorylated residues, only intensity corresponding to the resonance in the phosphorylated form is
indicated. Nt − N-terminus, Ct − C-terminus.
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Unlike p-tau(S262A)RBE, p-tauERK did not form ﬁbrils. NMR
analysis showed that the two forms of in vitro phosphorylated
wild-type tau shared 15 common phosphorylated sites and
diﬀered in only three sitesS208, S262, and S356which
were present in RBE- but not in ERK-phosphorylated tau.29
Comparison of these two forms suggested that the
phosphorylation of S208 was the key site necessary for
aggregation, as described by Despres et al.,30 because
phosphorylation of S262 and S356 had been reported
previously to inhibit aggregation.28 Therefore, S262, a site
that gets phosphorylated in vitro at a high level by RBE (in
contrast to S356), was substituted by Ala in subsequent
experiments to obtain an aggregation-prone isoform. Interest-
ingly, comparison of the oligomerization behavior of these two
forms showed that the aggregation-resistant p-tauERK formed a
variety of small (dimer through tetramer), medium (apparent
mobility corresponding to 800−1000 kDa), and large
(apparent mobility corresponding to 1100 kDa) oligomers,
whereas the aggregation-prone p-tau(S262A)RBE comprised a
mixture in which individual oligomers were less discernible and
high-molecular-weight species were prominent. Following
incubation, most of the p-tau(S262A)RBE preparation was no
longer visible in native PAGE/Western blot analysis (Figure
1E), presumably due to formation of large aggregates that did
not enter the gel.
Using the tau biosensor cell line developed by Diamond and
co-workers, we found, as expected, that tau ﬁbrils seeded
intracellular tau aggregation, regardless of whether they were
made of heparin-induced tau or p-tau(S262A)RBE (Figure 2A−
D). We were surprised, however, to discover that the
morphology and cellular distribution of the two forms
suggested that they belonged to distinct strains. Heparin-
induced tau ﬁbrils induced formation primarily of relatively
large cytoplasmic/perinuclear aggregates (Figure 2E), whereas
p-tau(S262A)RBE seeded small, primarily nuclear aggregates
(Figure 2F). These morphologies resembled the “ordered” and
“speckles” strains described recently by Kaufman et al.54 That
study found that tau from diﬀerent sources, including human
AD brain, cell lines from patients with diﬀerent tauopathies,
brain extract from the P301S mouse model, and recombinant
tau gave rise to various strains distinguished by the appearance
of the aggregates in the biosensor cells. Our data suggest that
heparin-induced tau ﬁbrils prepared under the conditions
described here and p-tau(S262A)RBE may allow obtaining
discrete strains reproducibly using recombinant tau for further
structural and biological studies. In agreement with previous
reports suggesting that tau seeding did not require ﬁbril
formation and could be mediated by oligomers, we found that
both forms of freshly dissolved in vitro phosphorylated tau, p-
tauERK and p-tau(S262A)RBE, though importantly not un-
phosphorylated tau, seeded tau aggregation in the biosensor
cells.
Before the current study, only two pieces of information
were available regarding the eﬀect of CLR01 on tau. Using the
ThT ﬂuorescence assay, equimolar concentration of CLR01
was shown to inhibit completely the aggregation of the shortest
form of tau, 0N3R, which was induced to aggregate by
arachidonic acid.75 In the presence of arachidonic acid, tau
aggregates into amorphous, rather than ﬁbrillar aggregates, and
therefore the eﬀect of CLR01 on ﬁbril formation was not
assessed in that study. The impact of CLR01 on tau aggregates
in vivo was examined in the triple-transgenic AD mouse model
expressing mutant forms of tau, amyloid β-protein precursor,
and presenilin-1. These mice accumulate both amyloid plaques
and NFTs in their brain with aging. Treatment of 14−15-
month-old mice, who already had both types of lesions, with a
low dose of CLR01 led to a substantial reduction in both
amyloid plaques and NFTs.90 Because tau pathology is thought
to be secondary to the neurotoxic eﬀects of amyloid β-protein
(Aβ), the study in the triple-transgenic mice could not reveal
whether the decrease in neuroﬁbrillary tangles was due to a
direct eﬀect of CLR01 on tau or an indirect eﬀect due to
inhibition of Aβ toxicity. Though the current study does not
address this question directly, it reveals that CLR01 eﬀectively
inhibits tau aggregation and intracellular seeding. The data also
demonstrate that the choice of the experimental system for
studying the eﬀect of the modulator is crucial.
When tau was induced to aggregate by heparin, CLR01
could interfere both with the induction itself and with the
intermolecular interactions among tau monomers that mediate
their further aggregation. Comparison of direct inhibition of
tau-heparin binding using SPR (Figure 4) and inhibition of tau
aggregation using ThT ﬂuorescence (Figure 5) suggested that
the main inhibitory activity of CLR01 was eﬀected on the self-
assembly of tau polypeptides rather than on tau−heparin
binding. Thus, the concentration of CLR01 needed for half-
maximal inhibition of tau aggregation was only twice the
concentration of tau, whereas 20-fold excess CLR01 was
needed for half-maximal inhibition of tau binding to heparin.
Consistent with the interpretation of eﬃcient inhibition of tau
self-assembly, CLR01 also eﬃciently inhibited the aggregation
of p-tau(S262A)RBE. Interestingly, however, the molecular
tweezer had a more complex eﬀect on the aggregation of the
protein in this case. At low concentrations, an initial
acceleration of ThT ﬂuorescence increase was observed,
whereas later in the aggregation reaction, the rate of increase
and the ﬁnal ﬂuorescence values were lower than that of p-
tau(S262A)RBE alone. Examination of the morphology at the
end of the reaction showed dose-dependent inhibition of ﬁbril
formation (Figure 6), suggesting that the initial increase in
ThT ﬂuorescence did not reﬂect formation of tau ﬁbrils, but
rather of a nonﬁbrillar, yet presumably β-sheet-rich structure.
Similar nonﬁbrillar structures displaying increased ThT
ﬂuorescence have been observed before in the presence of
CLR01 for other amyloidogenic proteins, including insulin, β2-
microglobulin, transthyretin, and p53 mutants.75,76 The details
of these structures are not known, but they seem to form when
CLR01 interacts with structured, rather than unstructured,
amyloidogenic proteins. If this trend holds true here too, it
would suggest that phosphorylation of tau may induce
formation of a more stable structure than that of
unphosphorylated tau. Interestingly, formation of a partially
structured conformation of tau recently has been suggested to
transform tau from a benign to a seeding-competent form,65 in
agreement with this idea. NMR studies also have highlighted
phosphorylation-induced conformational changes in the PRR
around the binding phospho-epitopes of antibodies AT8
(pS202/pT205)91 and AT180 (pT231/pS235)92,93 in which
phosphorylation stabilizes transient secondary structures. The
double phosphorylation at the AT8 epitope was shown to
induce a turn-like structure which protects tau from
aggregation, while a triple phosphorylation which includes
pS208 destabilizes this conformation and stimulates aggrega-
tion of phosphorylated tau.30
CLR01 binds to surface-exposed residues94 and therefore in
natively unstructured proteins would be expected to bind most
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or all of the Lys residues. However, previous studies with Aβ75
and α-synuclein95 have shown that certain residues are
preferred over others as binding sites. Here, we found that
CLR01 binds preferentially to Lys residues in the MTBD
(Figure 8, Supplementary Figure S5), possibly due to a high
concentration of acidic residues at the N- and C-terminal
regions that may repel the negatively charged molecular
tweezer (Supplementary Figure S6). An alternative explanation
is involvement of Lys residues in those regions in salt bridges
or other structural elements that prevent them from interacting
with CLR01. However, there is little evidence supporting the
existence of such structural elements, and the observation that
the interaction of CLR01 with the Lys residues in tau was not
aﬀected substantially by phosphorylation (Figure 9, Supple-
mentary Figures S9 and S10), which may increase structural
order, suggests against this explanation.
Our study demonstrates that heparin-induced tau aggrega-
tion yields distinct aggregation kinetics, oligomerization
patterns, and seeding behavior from those of in vitro
phosphorylated tau, which we hypothesize is a closer mimic
of the hyperphosphorylated tau in toxic oligomers and NFTs
in AD and other tauopathies. If our hypothesis is correct,
interpretation of studies using tau induced to self-assemble by
addition of heparin or other polyanions should be done with
caution. Testing modulators and inhibitors of tau self-assembly
and seeding in the presence of aggregation inducers is
particularly problematic due to the competition between the
inducer and the modulator for binding to tau. In vitro
phosphorylation of tau alleviates this problem and provides a
better mimic of disease-associated hyperphosphorylated tau.
Our data also suggest that CLR01 is an eﬀective inhibitor of
tau self-assembly and seeding. As CLR01 also has been shown
to be a potent inhibitor of Aβ self-assembly and toxicity in
vitro and in vivo,75,90,96,97 it may be a particularly attractive
lead for developing disease-modifying therapy thanks to its
ability to inhibit both of the oﬀending proteins in AD
simultaneously.
■ MATERIALS AND METHODS
Heparin sodium salt from porcine intestinal mucosa was purchased
from Sigma or Celsus Laboratories (Cincinnati, OH). Thioﬂavin T,
okadaic acid, Pefabloc, and all other chemicals, unless indicated
otherwise, were purchased from Sigma. For expression of isotopically
labeled tau, bacterial culture media were reconstituted using 13C6-
glucose 15NH4Cl,
15N/13C-ISOGRO, and 15N2,
13C6-L-lysine hydro-
chloride from Sigma-Aldrich (Isotec). Complete EDTA-free protease-
inhibitor cocktail was purchased from Roche. BCA colorimetric assay
was from Pierce. CLR01 was prepared as described previously55 and
puriﬁed as a sodium salt.
Production and Puriﬁcation of Recombinant Tau in
Isotopically Labeled and Unlabeled Forms. The 2N4R tau
isoform (residues 1−441 of human MAPT) in its wild-type or S262A
form, and the fragment F4 (tau residues 208−324) carrying a C322S
substitution were produced in the E. coli strain BL21(DE3) carrying a
pET15b recombinant plasmid (Novagen). Residue numbering of F4
is based on the 2N4R sequence. The wild-type mapt gene was
inserted into NcoI/XhoI cloning sites. The S262A substitution was
introduced by site-directed mutagenesis of the wild-type construct.
For uniform 15N-labeling, cells were grown at 37 °C in M9 minimal
medium containing 4 g/L glucose, 1 g/L 15N-NH4Cl, 0.5 g/L
15N-
Isogro (Sigma), 1 mM MgSO4, 100 μM CaCl2, MEM vitamin
cocktail, and 100 mg/L ampicillin. Expression was induced by
addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside for 3 h at
37 °C. For selective 15Nα,ε,
13C-Lys, and uniform 13C-labeling, the
same growth medium was used except that it contained 1 g/L of
unlabeled NH4Cl and 2 g/L
13C6-glucose and 150 mg
15N2,
13C-Lys
were added 20 min before induction. Cells were harvested by
centrifugation at 5000g for 30 min, and the pellet was resuspended in
50 mM NaH2PO4/Na2HPO4, pH 6.2, 2.5 mM EDTA, 2 mM DTT,
and 0.5% Triton X-100 supplemented with a Complete protease-
inhibitor cocktail. The lysate was obtained by homogenizing this
suspension using a high-pressure homogenizer followed by
centrifugation at 30000g for 30 min. The extract was incubated at
75 °C for 15 min to precipitate most of the bacterial proteins from the
soluble extract as a ﬁrst puriﬁcation step. The soluble proteins were
separated from the precipitate by centrifugation at 4000g for 20 min,
and the desired protein was puriﬁed by cation-exchange chromatog-
raphy (HiTrap SP HP 5 mL, GE Healthcare). The column was
equilibrated in 50 mM NaH2PO4/Na2HPO4, pH 6.4, 2 mM EDTA
(buﬀer A). The bacterial extract was loaded onto the column, and
then the column was washed with buﬀer A. The protein was eluted
with a gradient from 0% to 50% buﬀer B (buﬀer A supplemented with
2 M NaCl) over 20 mL (i.e., 4 column volumes). Elution fractions
were analyzed by SDS-PAGE, and fractions containing the pure
protein were pooled together for buﬀer-exchange in 50 mM
ammonium bicarbonate (HiPrep 26/10 desalting, GE Healthcare)
prior to lyophilization. Lyophilized proteins were stored at −20 °C or
−80 °C until further use.56 The recombinant tau proteins used in this
study are listed in Table 1 with an indication of phosphorylation sites
provided by the kinase activity of either activated ERK2 (ERK2*) or a
rat brain extract (RBE). These phosphorylation patterns are
consistent with those described previously.29,30
In Vitro Phosphorylation of Tau by Activated ERK2.
Recombinant ERK2 and a constitutively active MEK3 variant, a
mitogen-activated protein-kinase kinase that phosphorylates and
activates ERK2, were produced as described previously.29,56,57 15N-
or 15N2,
13C-Lys/13C-tau were dissolved at 100 μM with 1 μM of
ERK2 and ∼0.1 μM of MEK3 in 400 μL of buﬀer containing 50 mM
HEPES-KOH, pH 8.0, 12.5 mM MgCl2, 50 mM NaCl, 2 mM EDTA,
1 mM DTT, 1 mM EGTA, and 12.5 mM ATP. The mixtures were
incubated at 37 °C overnight. Enzymatic reactions were stopped by
incubating the reaction mixtures at 75 °C for 15 min followed by
centrifugation at 16000g for 20 min. Then, the supernates were buﬀer-
exchanged in 50 mM ammonium bicarbonate and lyophilized. Prior
to further analyses, phosphorylation was checked qualitatively by a
shift in the apparent mobility of the protein band on SDS-PAGE.
Then, the phosphorylated proteins were analyzed by high-resolution
NMR spectroscopy to determine the phosphorylation patterns and
potential protein degradation in a quantitative manner.29,57
In Vitro Phosphorylation of Tau by Rat Brain Extract (RBE).
RBE was prepared from adult Sprague−Dawley rats by homogenizing
whole brains (∼2 g) in 5 mL of homogenizing buﬀer, containing 10
mM Tris-HCl, pH 7.4, 5 mM EGTA, 2 mM DTT, 1 μM okadaic acid
(OA), 20 μg/mL leupeptin, and 40 mM Pefabloc. Insoluble material
was precipitated by ultracentrifugation at 100000g and 4 °C for 1 h.
The supernate was directly used for its kinase activity. Total protein
concentration was estimated at 11 mg mL−1 by a BCA colorimetric
assay. 15N,13C-tau-S262A was dissolved at 10 μM in 2.5 mL of
phosphorylation buﬀer, containing 40 mM HEPES, pH 7.3, 2 mM
MgCl2, 5 mM EGTA, 2 mM DTT, 2 mM ATP, and 1 μM OA,
supplemented with a Complete protease-inhibitor cocktail. The
protein was incubated with 500 μL of brain extract at 37 °C for 24
h. The enzymatic reaction was stopped by heating the mixture at 75
°C for 15 min followed by centrifugation at 16000g for 20 min. Then,
the supernate was buﬀer-exchanged in 50 mM ammonium
bicarbonate, and the protein was lyophilized. Qualitative evaluation
of protein phosphorylation was performed by SDS-PAGE, and then
the phosphorylation sites were determined by NMR analyses, as
described above.
In Vitro Aggregation Assay and Transmission Electron
Microscopy (TEM). For aggregation assays, unphosphorylated tau
was mixed with heparin at a ratio of 4:1, respectively, in a buﬀer
containing 25 mM NaH2PO4/Na2HPO4, pH 6.6, 25 mM NaCl, 2.5
mM EDTA, and 0.33 mM DTT at a ﬁnal protein concentration of 5
μM. Reactions carried out in the absence of heparin were used as a
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negative control. ThT was prepared freshly at 5 mM and added at a
ﬁnal concentration of 50 μM before measurements. ThT emission was
detected at 490 nm after excitation at 440 nm in 96-well plates on a
plate reader (PHERAStar, BMG LABTECH GmbH, Ortenberg,
Germany). Kinetic curves were ﬁtted to a plateau followed by a single
exponential association equation (eq 1).
= + − − − −Y Y Y Y( )(1 e )k t t0 max 0 ( )0 (1)
where t0 is the lag-time when nucleation occurs, k is the association
rate constant, Y0 is the value of the plateau at the initial step when t ≤
t0, Ymax is the maximal value of the plateau at the end of the elongation
step. Inhibition of aggregation by CLR01 was tested under the same
conditions by diluting a 10 mM stock solution of the molecular
tweezer in triply distilled water into the reaction mixture at diﬀerent
concentrations. Concentrations of CLR01 ranging from 1.25 to 20
μM were evaluated by 20 min step kinetics for a total of 92 h.
IC50 values were derived by ﬁtting the percentage of inhibition (eq
2) as a function of CLR01 concentration.
= −k k
k
%inhibition 0
0 (2)
where k is the association rate constants at a given concentration of
CLR01 and k0 is the rate constant in the absence of CLR01.
After completion of the aggregation, the morphology of the protein
alone or of Tau:CLR01 mixtures was examined by TEM. For these
experiments, 10-μL aliquots of the aggregation reactions were applied
to 400-meshed hexagonal Formvar-coated copper grids for 90 s. The
liquid was wicked oﬀ using a ﬁlter paper, and the grids were washed
thrice with ultrapure water, stained with 10 μL of 2% uranyl acetate
for 60 s, and wicked oﬀ using a ﬁlter paper. TEM was performed using
a HITACHI H7500 microscope at 80 kV.
Aggregation assays using tau phosphorylated by RBE (p-tau-
(S262A)RBE) were performed at 30 μM of the protein in a buﬀer
containing 100 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.9, 2
mM EGTA, 1 mM MgCl2, 20 mM NaF, 0.33 mM DTT, and 50 μM
ThT. p-tau(S262A)RBE was incubated without agitation for 5 days at
37 °C in the absence or presence of 7.5, 15, 22.5, 30, 60, or 120 μM
CLR01, and aggregation kinetics was followed by ThT ﬂuorescence.
At the end of incubation, samples were analyzed by TEM as described
above.
Preparation of Tau Seeds. To evaluate the seeding capability of
tau, the diﬀerent variants either were freshly dissolved and tested
immediately or incubated at 37 °C for 5−10 days to form ﬁbrils
before addition to biosensor cells. Unphosphorylated tau was
incubated in the presence of heparin or in the absence of heparin
as a negative control, whereas tau phosphorylated by ERK2 (p-
TauERK) or p-tau(S262A)RBE was incubated in the absence of heparin.
Before preparing transduction complexes, the proteins were sonicated
for 10 min in a bath sonicator. Transduction complexes were made by
combining a solution of 8.75 μL Opti-MEM (Gibco) and 1.25 μL of
lipofectamine 2000 (Invitrogen) with a solution/suspension of tau
seeds in Opti-MEM at the desired concentration, determined using
the BCA colorimetric assay for a total volume of 20 μL per well. The
concentration was calculated based on tau monomer. Transduction
complexes were incubated at RT for 20 min before adding to cells.
Transduction of Tau Seeds in Biosensor Cells. A monoclonal,
FRET-based biosensor cell line58 was maintained as described in
instructions from ATCC (CRL-3275). Brieﬂy, the cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM,
ATCC-30-2002) supplemented with 2 mM L-alanyl-L-glutamine and
10% fetal bovine serum (FBS) under a 5% CO2 atmosphere at 37 °C.
These cells stably express the tau MTBD containing the disease-
associated substitution P301S and fused to either cyan ﬂuorescent
protein (CFP) or yellow ﬂuorescent protein (YFP).58 The cells were
plated at 35 000 cells per well in 96-well plates (Sigma-Aldrich).
Eighteen hours later, at ∼60% conﬂuency, the cells were transduced
with tau seeds and incubated with the seeds for 24−48 h prior to ﬂow
cytometry analysis.
FRET Flow Cytometry. Cells were incubated in 50 μL of TrypLE
(Cat. 12605010, ThermoFisher) per well for 5 min at 37 °C followed
by addition of 150 μL of DMEM supplemented with 2 mM L-alanyl-L-
glutamine and 10% fetal bovine serum to stop the reaction. The cells
were transferred to a round-bottom 96-well plate (Cat. 07-200-89,
ThermoFisher), centrifuged at 400g for 5 min, and then resuspended
in 200 μL of ﬂow cytometry buﬀer comprising 1% FBS and 1-mM
EDTA in Hank’s balanced salt solution (GIBCO). A SORP BD
Biosciences HTLSRII analytic ﬂow cytometer was used for FRET
ﬂow cytometry measurements. To measure CFP and FRET, cells were
excited using a 405 nm laser, and ﬂuorescence was captured using
405/50 nm and 525/50 nm ﬁlters, respectively. To measure YFP, cells
were excited using a 488 nm laser, and ﬂuorescence was captured with
a 525/50 nm ﬁlter. To quantify FRET, we used a gating strategy
similar to that described previously.58 Brieﬂy, CFP bleed-through into
the YFP and FRET channels was compensated for using FACSDiva
8.0.1 software from BD Biosciences. Because some YFP-only cells
exhibit emission in the FRET channel, we introduced an additional
gate to exclude from analysis cells that generate a false-positive signal
in the FRET channel (i.e., false FRET gate). Subsequently, we created
a ﬁnal bivariate plot of FRET vs CFP and introduced a triangular gate
to assess the number of FRET-positive cells. This FRET gate was
adjusted to biosensor cells treated with lipofectamine but no tau
seeds, which are thus FRET-negative. This allows for direct
visualization of sensitized acceptor emission arising from excitation
of the CFP donor at 405 nm. The integrated FRET density, deﬁned as
the percentage of FRET-positive cells multiplied by the median
ﬂuorescence intensity of FRET-positive cells, was used for all analyses.
For each experiment, 20 000 cells per replicate were analyzed, and
each condition was analyzed in quadruplicate. Data analysis was
performed using Flow Jo v10 (Treestar).
Native PAGE/Western Blots. Recombinant protein aliquots from
seeding experiments were mixed with 4X NativePAGE sample buﬀer,
containing 50 mM Bis-Tris, 6 N HCl, 50 mM NaCl, 10% v/v glycerol,
and 0.001% w/v Ponceau S, pH 7.2. Ten microliters sample per well
were loaded onto Novex NativePAGE 3−12%-gradient Bis-Tris gels
(Thermo Fisher). The proteins were fractionated for 90−115 min at
150 V constant voltage using a XCell SureLock Mini-Cell system
(ThermoFisher). The proteins then were transferred to a PVDF
membrane for 1 h at 25 V constant voltage using a XCell II Blot
Module (ThermoFisher). Membranes then were incubated in 20 mL
of 8% acetic acid for 15 min to ﬁx the proteins. The blots were probed
with antihuman tau mAb HT7 diluted 1:1000 in 5% (v/v) nonfat dry
milk in TBST. ECL Plus (GE Healthcare) was used to visualize the
bands in a Syngene PXi multiapplication gel imaging system, and
band intensity was quantiﬁed densitometrically using ImageJ.59,60
Surface Plasmon Resonance. Biotinylated heparin was prepared
by reaction with amine-PEG3-Biotin (Pierce, Rockford, IL) in the
presence of NaCNBH3 as described previously.
61 The biotinylated
heparin was immobilized on a streptavidin (SA) chip (GE
Healthcare) based on the manufacturer’s protocol. Brieﬂy, 20 μL of
0.1 mg mL−1 of the biotinylated heparin in HBS-EP running buﬀer
(0.01 M HEPES, 0.15 M NaCl, 3 mM EDTA, and 0.005% surfactant
P20, pH 7.4) were injected over ﬂow cells 2, 3, and 4 of the SA chip at
a ﬂow rate of 10 μL/min. The successful immobilization of heparin
was conﬁrmed by the observation of a ∼200-resonance-unit (RU)
increase in the sensor chip. The control ﬂow cell was prepared by a 1
min injection of saturated biotin. Tau was dissolved in HBS-EP buﬀer,
and diﬀerent dilutions of the protein solution were injected at a ﬂow
rate of 30 μL/min. At the end of the sample injection, the same buﬀer
was ﬂowed over the sensor surface to facilitate dissociation. After a 3
min dissociation period, the sensor surface was regenerated by
injection of 30 μL of 2 M NaCl. The response sensograms were
monitored as a function of time at 25 °C. For testing the inhibition of
the tau−heparin interaction by CLR01, 500 nM of tau was mixed with
0, 5, 12.5, 25, or 50 μM CLR01. Then, each mixture was injected over
the heparin chip at a ﬂow rate of 30 μL/min. At the end of the sample
injection, the same buﬀer was ﬂowed over the sensor surface to
facilitate dissociation and the sensor surface was regenerated as
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described above. The highest response was obtained for calculation of
normalized binding inhibition.
NMR Spectroscopy. Spectra were acquired at 293 K on a Bruker
900-MHz spectrometer equipped with a triple-resonance cryogenic
probe head. 15N-Lys-labeled tau was dissolved at 200 μM in NMR
sample buﬀer, containing 50 mM NaH2PO4/Na2HPO4, pH 6.4, 25
mM NaCl, 2.5 mM EDTA, 1 mM DTT, and 10% D2O in 3 mm NMR
tubes. The proton frequency was calibrated with 1 mM sodium 3-
(trimethylsilyl)propionate-2,2,3,3-d4 as a reference.
1H−15N HSQC
spectra were recorded for 15N- and 15N,13C-labeled samples with 64
scans per increment, and 3072 and 512 points in the 1H and 15N
dimensions, respectively.
The phosphorylation patterns of p-tauERK, p-tauRBE, and p-
tau(S262A)RBE were analyzed as described previously.56,57 The
patterns (Table 1) were similar to those characterized previously by
Despres et al.30 and Qi et al.29 For 15N,13C-Lys,13C-labeled p-tau
assignment, a three-dimensional HN(CO)CACB experiment was
performed with 16 scans per increment. Spectral widths were 16.0,
23.0, and 61.0 ppm in the 1H, 15N, and 13C dimensions with 2048, 64,
and 120 sample points, respectively.
For the NMR mapping of protein resonance intensities upon
CLR01 binding, the intensity of each resonance in the 1H−15N
HSQC spectrum in the presence of CLR01 (I) was determined and
compared to the resonance intensity in the absence of CLR01 (I0).
The normalized intensities I/I0 were plotted as a function of the
protein sequence.
For aggregation assays, protein concentrations were normalized
based on their 1D proton spectra (zggpw5, Bruker) acquired at 600
MHz with 64 scans, 16 dummy scans and 16 384 points for a spectral
width of 13.97 ppm centered on 4.70 ppm.
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